2022-501322-38-00
Suspended
Phase 2
The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a non-randomized, open-label, single-arm phase II study
Institut fuer Klinische Krebsforschung IKF GmbH2 sites in 1 country46 target enrollmentStarted: March 30, 2023Last updated:
Overview
- Phase
- Phase 2
- Status
- Suspended
- Sponsor
- Institut fuer Klinische Krebsforschung IKF GmbH
- Enrollment
- 46
- Locations
- 2
- Primary Endpoint
- • Major pathological response (MPR) rate after curative intent surgery
Overview
Brief Summary
The objective of this study is to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as inductive and adjuvant treatment for surgical NSCLC patients.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Has provided written informed consent
- •The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
- •The patient is willing and able to provide liquid and tissue samples for the accompanying translation project.
- •Adequate bone marrow and renal function including the following: • Hemoglobin ≥ 9.0 g/dL • Absolute neutrophil count ≥ 1.0 x 109/L • Platelets ≥ 75 x 109/L • Calculated creatinine clearance ≥30 mL/min as determined by the Cockcroft-Gault equation
- •Adequate hepatic function (with stenting for any obstruction, if required) including the following: • Serum bilirubin ≤ 3 x institutional upper limit of normal (ULN) • AST (SGOT) / ALT (SGPT) and alkaline phosphatase ≤ 2.5x ULN
- •Female patients who are considered as women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- •Female patients who are considered as WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as up to 5 months after the last dose of IMP. Male patients who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as at least 5 months after the last dose of IMP. Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, see section 5.1.5) as well as azoospermic male patients do not require contraception.
- •Patient* 18 years or older at time of signing informed consent form
- •Histologically confirmed NSCLC of squamous or non-squamous histology
- •Resectable clinical stage II, IIIA and IIIB (T3N2 only) NSCLC (according to UICC 8)
Exclusion Criteria
- •Treatment in any other clinical trial with an investigational product within 30 days before screening
- •Positive testing for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV) RNA indicating acute or chronic infection. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Positive testing for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 5 months after the last dose of atezolizumab/tiragolumab.
- •Active or prior documented autoimmune or inflammatory disorders (including but not limited to diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener’s syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: • Patients with vitiligo or alopecia • Patients with hypothyroidism (e.g., following Hashimoto’s disease) stable on hormone replacement • Patients with controlled Type I diabetes mellitus on an insulin regimen • Any chronic skin condition that does not require systemic therapy • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
- •Active, uncontrolled inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]. Patients in stable remission for more than 1 year may be included.
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, interstitial lung disease, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of atezolizumab/tiragolumab. The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection) • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent • Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
- •Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
- •History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, drug-induced pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan.
Outcomes
Primary Outcomes
• Major pathological response (MPR) rate after curative intent surgery
• Major pathological response (MPR) rate after curative intent surgery
Secondary Outcomes
No secondary outcomes reported
Investigators
Clinical Trial project manager
Scientific
Institut fuer Klinische Krebsforschung IKF GmbH
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerNCT07290621University of Chicago30
Not yet recruiting
Not Applicable
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaNCT07268131Fudan University30
Recruiting
Not Applicable
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45
Not yet recruiting
Not Applicable
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARCNCT07291401Zhongnan Hospital108
Not yet recruiting
Phase 2
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)NCT07283692RenJi Hospital46